# Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes

> **NCT00982644** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 1030 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin degludec
- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT00982644
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 1030 (ACTUAL)
- **Last updated:** 2017-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00982644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00982644, "Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00982644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*